NCT02566681Unknown1 期
Phase I Clinical Trial of Use of Autologous Bone Marrow Stem Cells Seeded on Porous Tricalcium Phosphate Matrix and Demineralized Bone Matrix in Patients With Osteonecrosis (MSC/ONM)
适应症
试验速览
- 阶段
- 1 期
- 入组人数
- 10
- 试验地点
- 2
- 主要终点
- Rate of non-serious adverse events related to the procedure.
研究概览
简要总结
The purpose of this study is to evaluate the safety of use of autologous bone marrow stem cells seeded on porous tricalcium phosphate matrix and demineralized bone matrix in patients with osteonecrosis of the jaw by a prospective, single-center, open, nonrandomized and unblinded clinical trial.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 85 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Diagnosis of mandibular osteonecrosis of any etiology defined by clinical and radiological examination.
- •Bone defect anteroposterior dimension less than or equal to 4 cm in the mandible or the maxilla 2.5, and / or bone bed sufficient to ensure the integrity of the construct during surgery.
- •No response to conservative treatment.
- •Provide sufficient assurance of adherence to protocol.
- •Provide written consent
- •Meet all the inclusion criteria
排除标准
- •Concomitant psychiatric illness.
- •Uncontrolled concomitant systemic disease.
- •Active infectious disease in the focus of mandibular osteonecrosis.
- •Neoplastic disease in complete remission less than 2 years.
- •Pregnant patients.
- •Patients with active feeding.
- •Patients physically fertile, defined as all women physiologically capable of becoming pregnant, UNLESS they are using reliable methods of contraception.
- •Patients with cardiac disease, renal, hepatic, systemic, immune that may influence patient survival during the test.
- •Inclusion in other clinical trials in active treatment.
- •Inability to understand the informed consent.
- •You need not meet any exclusion criteria
结局指标
主要结局
Rate of non-serious adverse events related to the procedure.
时间窗: 24 months from baseline
Local infection of the surgical wound. Pseudarthrosis implant. Allergic reactions.
Rate of serious adverse events related to the procedure.
时间窗: 24 months from baseline
Apparition of Bone ischemic events. Neoformations.
次要结局
- Time to Repair the injury(24 months from baseline)
- Quality of life, measured by EuroQol-5D.(24 months from baseline)
- Local pain assessed by visual analog scale(24 months from baseline)
- Bone formation, measured by Computed tomography (mm)(24 months from baseline)
研究者
研究点 (2)
Loading locations...
相似试验
已完成
1 期
Stem Cell Gene Therapy for Sickle Cell DiseaseSickle Cell DiseaseNCT02247843Donald B. Kohn, M.D.4
已完成
1 期
Autologous Bone Marrow Stem Cells Transplantation in Patients With Temporal Lobe EpilepsyEpilepsyNCT00916266Instituto do Cerebro de Brasilia20
已完成
1 期
Intrathecal Administration of Autologous Mesenchymal Stem Cell-derived Neural Progenitors (MSC-NP) in Patients With Multiple SclerosisMultiple SclerosisNCT01933802Tisch Multiple Sclerosis Research Center of New York20
已完成
1 期
Study of Autologous Stem Cell Transplantation for Patients With Ischemic StrokeInfarction, Middle Cerebral ArteryNCT00473057Universidade Federal do Rio de Janeiro12
已完成
1 期
Safety and Efficacy Study of Autologous Bone Marrow Derived Stem Cell Treatment in Amyotrophic Lateral SclerosisAmyotrophic Lateral SclerosisALSNCT01363401Corestemchemon, Inc.72